



# Frequency of *qnr* and *aac(6')Ib-cr* Genes Among ESBL-Producing *Klebsiella pneumoniae* Strains Isolated from Burn Patients in Kermanshah, Iran

Siavash Vaziri <sup>1</sup>, Mandana Afsharian <sup>1</sup>, Feizollah Mansouri <sup>1</sup>, Mohsen Azizi <sup>2</sup>, Fatemeh Nouri <sup>3</sup>, Nahid Madadi-Goli <sup>4</sup>, Zainab Mohseni Afshar <sup>1</sup>, Mohammad Hossein Zamanian <sup>1</sup>, Amirhooshang Alvandi <sup>2</sup> and Kamal Ahmadi <sup>2, 4, \*</sup>

<sup>1</sup>Department of Infectious Disease, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

<sup>2</sup>Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

<sup>3</sup>Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran

<sup>4</sup>Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran

\*Corresponding author: Research Assistant, Kermanshah University of Medical Sciences, and Ph.D. Student of Medical Bacteriology, Pasteur Institute of Iran, Tehran, Iran.  
Email: k\_ahmadi@pasteur.ac.ir

Received 2019 December 28; Revised 2020 August 09; Accepted 2020 August 31.

## Abstract

**Background:** Assessment of bacteria such as *Klebsiella pneumoniae* has shown that Plasmid-mediated quinolone resistance (PMQR) affects antibiotics resistance (e.g., quinolones).

**Objectives:** We studied the prevalence of *qnr* and *aac(6')Ib-cr* genes in extended-spectrum beta-lactamase (ESBL)-producing *K. pneumoniae* strains isolated from burn wounds of patients in the city of Kermanshah, Iran.

**Methods:** This descriptive-analytical study was conducted on 126 *K. pneumoniae* strains isolated collected from burn wounds. Biochemical tests were used to detect the strains. The frequency of the ESBL-producing isolates was determined by phenotypic tests of the combination disk (CD) method after determining the antibiotic susceptibility pattern of the isolates through the Kirby-Bauer disc diffusion test. The prevalence of the *qnr* and *aac(6')Ib-cr* genes was determined using their special primers as well as polymerase chain reaction (PCR).

**Results:** Of the 126 *K. pneumoniae* isolates, 52 (41.3%) were identified as ESBL-producing strains. ESBL-producing isolates showed higher resistance against antibiotics than non-ESBL-producing ones. PMQR relevance and resistance to ciprofloxacin were, respectively, determined at 80.76% and 59.6%. The most frequent gene was *aac(6')Ib-cr* (n = 70, 55.6%), followed by the *qnrB* (n = 44, 34.9%).

**Conclusions:** This study showed a high prevalence of *qnr* genes in ESBL-producing *K. pneumoniae* isolates and antibiotic resistance. Given the horizontal transmission of antibiotic resistance genes among bacteria by mobile genetic elements, timely identification of infections caused by ESBL-producing and antimicrobial-resistant *K. pneumoniae* strains is of paramount importance.

**Keywords:** *Klebsiella pneumoniae*, Quinolone Resistance, Drug Resistance

## 1. Background

Nosocomial infections, also known as hospital-acquired infections, are common in burn patients due to the special features of the diseases, such as skin damage, physiological changes, prolonged hospitalization, and receiving aggressive interventions (1). *Klebsiella pneumoniae* belongs to the *Enterobacteriaceae* family and is described as a gram-negative, encapsulated, and lactose-fermenting bacteria (2) that is responsible for various hospital-acquired infections such as pneumonia, septicemia, diarrhea, liver abscess, endophthalmitis, meningitis, urinary tract infections, and bacteremia,

whose mortality rates are high (3). Along with other gram-negative bacteria such as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*, *K. pneumoniae* pathogens are commonly isolated from patients with burn infections (4). Most of such infections are caused by multidrug-resistant (MDR) strains that interrupt the treatment processes (5). Besides, extended-spectrum beta-lactamase (ESBL)-producing *K. pneumoniae* isolates are highly resistant to antibiotics, which further complicate infections and the treatment processes of burn patients. Moreover, MDR strains are resistant against beta-lactam antibiotics and different types of antibiotics, including quinolones and

aminoglycosides (6). Quinolones and fluoroquinolones extensively use for the treatment of *K. pneumonia*-induced infections, mainly because of the resistance of these bacteria to the first-line drugs, which have led to a significant increase in resistance against them (7).

Plasmid-mediated quinolone resistance (PMQR) is mediated by the *qnr* genes, boosting antimicrobial resistance among bacteria due to their placement on mobile genetic elements. Therefore, PMQR also plays a significant role in quinolone resistance due to its high emission potential among *Enterobacteriaceae* (8). Three types of PMQR genes are identified so far, including the *qnr*, which is the most important one (9). In addition to resistance to quinolones, PMQR can be similarly effective in resistance against other antibiotics, especially beta-lactams and aminoglycosides (10). To date, five *qnr* groups are identified, including the *qnrA*, *qnrB*, *qnrC*, *qnrD*, and *qnrS*. Moreover, PMQR can exert its influence through two further mechanisms of *QepA* and *OqxAB* pumps and an aminoglycoside acetyltransferase known as the *aac(6′)-Ib-cr*, which cause reduced susceptibility against ciprofloxacin (9, 11, 12). The *qnr* genes also cause resistance against quinolones via inhibiting DNA gyrase and topoisomerase IV. Alongside aminoglycoside resistance, the *aac(6′)-Ib-cr* gene can correspondingly cause resistance against fluoroquinolones (13).

## 2. Objectives

No recent comprehensive research is performed on the prevalence rates of PMQR genes in *K. pneumonia* isolates among patients in the city of Kermanshah, Iran. Therefore, the present study aimed to determine the frequency of the *qnrA*, *qnrB*, *qnrS*, and *aac(6′)-Ib-cr* genes in *K. pneumonia* strains of burn wound infections collected from patients in the city of Kermanshah, Iran.

## 3. Methods

### 3.1. Isolate Collection and Recognition

The current descriptive-analytical study was conducted on 465 clinical samples collected from burn patients admitted to Imam Khomeini Hospital in Kermanshah from August 2017 to June 2018, who had burn wounds with no history of antibiotics consumption for more than a week. After collection, samples were immediately transferred to the laboratory under sterile conditions. Then, samples were cultured onto eosin methylene blue agar (EMB) and MacConkey agar (Merck Group, Germany) and subsequently incubated for 24 h at 37°C. In total, 126 *K. pneumonia* isolates were detected using standard biochemical tests through culturing in triple sugar iron

agar (TSI), sulfur-indole-motility (SIM), methyl red-Voges Proskauer (MRVP), citrate, and urea broths (3) (HiMedia Laboratories Pvt. Ltd., India). Afterward, the identified *K. pneumonia* samples were maintained in trypticase soy broth (TSB) treated with 15% glycerol (-70°C).

### 3.2. Antibiotic Susceptibility Testing (AST)

The antimicrobial susceptibility patterns of samples were assessed via disk diffusion test based on the guidelines of the Clinical and Laboratory Standards Institute (CLSI) (14) for ciprofloxacin (5 µg), levofloxacin (5 µg), enrofloxacin (10 µg), ofloxacin (5 µg), gatifloxacin (5 µg), nalidixic acid (30 µg), gentamicin (10 µg), amikacin (30 µg), ceftazidime (30 µg), cefotaxime (30 µg), ceftriaxone (30 µg), and aztreonam (30 µg), as antibiotics provided by MAST (the United Kingdom). In cases that matching with the density of the 0.5 McFarland standards ( $1.5 \times 10^8$ ) was required, the concentration of the bacteria was used for antimicrobial susceptibility testing. The *K. pneumonia*, the American Type Culture Collection (ATCC) 700603, and the *Escherichia coli*, ATCC 25922 were further applied to ensure the quality of the antimicrobial susceptibility tests (3, 10).

### 3.3. ESBL Confirmation by Combination Disk (CD) Method

Isolates with a minimum inhibition zone diameter of 22, 25, and 27 mm, respectively, for ceftazidime, ceftriaxone, and cefotaxime were assessed for detecting ESBL genes. To confirm ESBL production, the CD method was further performed using 30 µg cefotaxime and ceftazidime disks impregnated with 10 µg clavulanic acid (MAST, the United Kingdom) on Mueller-Hinton agar (HiMedia Laboratories Pvt. Ltd., India) similar to the disc diffusion method. On the other hand, the strains with a minimum inhibition zone diameter equal to or more than 5 mm, in comparison with the single disc of the same antibiotic, were regarded as ESBL-producing (15).

### 3.4. Polymerase Chain Reaction (PCR)

After extracting the deoxyribonucleic acid (DNA) of the isolates by boiling, the frequency of the *qnrA*, *qnrB*, *qnrS*, and *aac(6′)-Ib-cr* genes was assessed using the PCR through special primers (Takapou Zist Co., Iran) (10), as shown in Table 1. The concentration of the DNA samples was determined at wavelength 260 nm using a NanoDrop Synergy HTX (Bio Tek Instrument, Inc Highland Park, USA) equal to 35 pmol/ul. Also, the purity of the extracted DNA at 260/280 nm was 1.85. PCR was accordingly performed using the total 25 µL volume, including Master mix (12.5 µL) (Sinoclon Co., Iran), 1 µL of the primers, bacterial DNA (2 µL), and sterilized distilled water until reaching 25 µL. The following stages were included in the PCR protocol: initial denaturation (94°C/5 min), 30 main cycles according to Table 1,

and extension (10 min/72°C). The *E. coli* J53 strains, including pMG252, pMG298, and pMG306, were also considered, respectively, as positive controls of the *qnrA*, *qnrB*, and *qnrS* genes. Then, 1% agarose gel was applied for electrophoresis of the PCR yields, and the product was consequently stained by ethidium bromide.

### 3.5. Statistical Analysis

Data were analyzed using the IBM SPSS Statistics version 20 via the chi-square test and Fisher's exact test. As well, P values less than 0.05 were considered statistically significant.

## 4. Results

Analyzing 126 *K. pneumonia* isolates showed a prevalence of 73 (57.9%) and 53 (42.1%) for males and females, respectively. The mean age of participants was  $36.11 \pm 48.42$ , and the youngest and oldest participants were 11 and 73 years, respectively. Most of the isolates (44 or 34.9%) with *K. pneumonia* were taken from patients aged 31 to 45 years, and the lowest was from patients less than 6 years (6 or 4.8%). All isolates were obtained from patients with burn wounds admitted to Imam Khomeini Hospital in the city of Kermanshah (Iran). The prevalence rate of MDR isolates was 54.8% (69 isolates). Based on the findings of the phenotypic test, 52 (41.3%) isolates (out of the 126) were ESBL-producing. In the positive ESBL isolates, the frequency of MDR isolates was 46 (88.5%). According to Table 2, the ESBL-producing isolates indicated more antimicrobial resistance than non-ESBL-producing samples ( $P < 0.05$ ). The highest antimicrobial resistance level in ESBL-producing and non-ESBL-producing *K. pneumonia* isolates was against ceftriaxone (90.4%) and nalidixic acid (47.3%), respectively. In addition, the highest level of susceptibility in ESBL-producing and non-ESBL-producing samples was, respectively, against gatifloxacin (40.4%) and amikacin (10.9%) (Table 2).

Furthermore, PMQR genes were detected in 62.7% ( $n = 79$ ) of 126 *K. pneumonia* isolates, of which 80.76% ( $n = 42$ ) isolates were ESBL-producing. *aac(6)-Ib-cr* was the most common gene resistant against quinolones ( $n = 70$ , 55.6%), followed by the *qnrB* ( $n = 44$ , 34.9%). Moreover, the simultaneous presence of resistance genes was observed in 37 strains with the *qnrB* and *aac(6)-Ib-cr* (Figure 1). ESBL-producing samples correspondingly revealed more frequency regarding these genes (Table 3). These results indicated a significant correlation between the *qnrB* and *aac(6)-Ib-cr* genes and resistance against most of the evaluated antibiotics, especially cephalosporins and aminoglycosides ( $P < 0.05$ ). The PCR results for the detection of these genes are described in Figure 2.

## 5. Discussion

*Klebsiella pneumonia* is an opportunistic emerging pathogen that causes nosocomial infections. Quinolones are commonly used for treating infections caused by the *Enterobacteriaceae* species, including *K. pneumonia*. On the other hand, increased resistance to these antibiotics is associated with severe therapeutic outcomes (16). The present study aimed to evaluate the prevalence of quinolone resistance genes in ESBL-producing *K. pneumoniae* strains isolated from burn wounds. Most of the *K. pneumonia* positive isolates were found in males aged 31 to 45 years. Of the 126 *K. pneumonia* isolates, 69 (54.8%) were MDR and 52 (41.3%) ESBL-producing. According to the literature, the prevalence of ESBL-producing strains in Iran ranges from 12 to 72% (17-19). More than 88% of positive ESBL isolates were MDR.

Based on the previous studies, the frequency of MDR in the ESBL-producing *K. pneumonia* isolates ranges from 63.33 to 92%. That is consistent with the findings of the current study (5, 20-22). Accordingly, more than 86% of ESBL-producing strains were resistant against cephalosporins. Meanwhile, a study conducted in Iran has reported that almost all ESBL-producing strains were resistant to these antibiotics (23). Based on the findings, in the present study, the resistance of the ESBL-producing strains against aminoglycosides (68.3%) was higher than those reported by Goudarzi et al. (46.35%), Shams et al. (45%), and Eftekhari (36.7%) (10, 13, 22). Moreover, more than 50% of the ESBL-producing *K. pneumonia* isolates were resistant against fluoroquinolones, and the highest and lowest resistance was, respectively, found against nalidixic acid (65.4%) and gatifloxacin (40.4%). According to studies conducted in Iran, 37.5-80% of ESBL-producing *K. pneumonia* isolates are resistant to ciprofloxacin (10, 22, 24). In the present study, resistance against this antibiotic was 59.6% in ESBL-producing isolates. The global trend of resistance to fluoroquinolones in ESBL-producing bacteria is on the rise (25). Nevertheless, these conflicting results may be due to the difference in antibiotic susceptibility patterns, treatment regimens, types of isolates, geographical differences, and variations in health care control systems at medical centers (3).

PMQR genes play a significant role in resistance against quinolones and fluoroquinolones among ESBL-producing *K. pneumonia* isolates. The association between PMQR genes with resistance to quinolone and antibiotic-resistant *K. pneumonia* is reported by several studies (26). Most of the resistant isolates were found in *K. pneumonia* isolates (27, 28). In the present study, 79 (62.7%) out of 126 *K. pneumoniae* isolates harbored PMQR genes. However, PMQR determinants were found in 80.76% of ESBL-producing isolates. Based on the studies conducted in

**Table 1.** Primers and Temperature Cycles Used in PCR (30 Cycles)

Primer	Sequence (5'-3')	Denaturation, 94°C	Annealing, 1 min	Extension, 72°C	Product Size (bp)
<i>qnrA</i>	TTCTCACGCCAGGATTGAG TGCCAGGCACAGATCTTGAC	1 min	57°C	1 min	571
<i>qnrB</i>	TGGCGAAAAAATTGAACAGAA GAGCAACGATCGCCTGGTAG	1 min	57°C	1 min	594
<i>qnrS</i>	GACGTGCTAACTGCGTGAT AACACCTCGACTTAAGTCTGA	1 min	57°C	1 min	388
<i>aac(6')-Ib-cr</i>	TTGCGATGCTCTATGAGTGGCTA CTCGAATGCCTGGCGTGTTT	1 min	54°C	1 min	482

**Table 2.** Results of Antibiotic Resistance Patterns in Positive and Negative ESBL-producing *Klebsiella pneumoniae* Isolates<sup>3</sup>

Antibiotics	All Strains (N = 126)			ESBL Positive (N = 52)			ESBL Negative (N = 74)			P Value
	R	S	I	R	S	I	R	S	I	
NA	69 (54.8)	51 (40.5)	6 (4.8)	34 (65.4)	16 (30.8)	2 (3.8)	35 (47.3)	35 (47.3)	4 (5.4)	0.108
CIP	66 (52.4)	52 (41.3)	8 (6.3)	31 (59.6)	16 (30.8)	5 (9.6)	35 (47.3)	36 (48.6)	3 (4.1)	0.030 <sup>b</sup>
LEV	43 (34.1)	76 (60.3)	7 (5.6)	23 (44.3)	29 (55.7)	0	20 (27)	47 (63.5)	7 (9.5)	0.875
OFX	48 (38.1)	72 (57.1)	6 (4.8)	24 (46.2)	26 (50)	2 (3.8)	24 (32.4)	46 (62.2)	4 (5.4)	0.320
NOR	59 (46.8)	58 (46)	9 (7.1)	27 (52)	23 (44.3)	2 (3.8)	32 (43.2)	35 (47.3)	7 (9.5)	0.820
GAT	38 (30.2)	88 (69.8)	0	21 (40.4)	31 (59.6)	0	17 (23)	57 (77)	0	0.029 <sup>b</sup>
AK	42 (33.3)	82 (65.1)	2 (1.6)	34 (65.4)	17 (32.7)	1 (1.9)	8 (10.9)	65 (87.8)	1 (1.3)	0.0001 <sup>b</sup>
GM	52 (41.3)	72 (57.1)	2 (1.6)	37 (71.2)	14 (26.9)	1 (1.9)	15 (20.3)	58 (78.4)	1 (1.3)	0.0001 <sup>b</sup>
CTX	57 (45.2)	69 (54.8)	0	45 (86.5)	7 (13.5)	0	12 (16.2)	62 (83.8)	0	0.0001 <sup>b</sup>
CAZ	52 (41.3)	72 (57.1)	2 (1.6)	43 (82.7)	19 (17.3)	0	9 (12.2)	63 (85.1)	0	0.0001 <sup>b</sup>
CRO	61 (48.4)	65 (51.6)	0	47 (90.4)	5 (9.6)	0	14 (19)	60 (81)	0	0.0001 <sup>b</sup>
ATM	51 (40.5)	75 (59.5)	0	42 (80.8)	10 (19.2)	0	9 (12.2)	65 (87.8)	0	0.0001 <sup>b</sup>

Abbreviations: AK, Amikacin; ATM, Aztreonam; CAZ, Ceftazidime; CIP, Ciprofloxacin; CRO, Ceftriaxone; CTX, Cefotaxime; GAT, Gatifloxacin; GM, Gentamicin; LEV, Levofloxacin; NA, Nalidixic Acid; NOR, Norfloxacin; OFX, Ofloxacin

<sup>a</sup>Values are expressed as No. (%).

<sup>b</sup>Significant

**Table 3.** Frequency of Genes in Positive and Negative ESBL-producing *Klebsiella pneumoniae* Isolates


Genes	ESBL Positive	ESBL Negative	P Value
<i>qnrA</i>	0	0	-
<i>qnrB</i>	24	20	0.022 <sup>a</sup>
<i>qnrS</i>	6	4	0.179
<i>aac(6')-Ib-cr</i>	39	31	0.0001 <sup>a</sup>

<sup>a</sup>Significant


Iran, the prevalence of PMQR genes in *K. pneumoniae* isolates ranges from 39.5 to 89.1% (10, 13, 26, 27, 29, 30), while in other countries it ranges from 11.1 to 100% (e.g., South Korea, the United States, and Syria) (31-33). Generally, susceptibility to quinolones and aminoglycosides is lower in species harboring the acetyltransferase *aac(6')-Ib-cr* gene. In this study, the most common plasmid gene in *K. pneumoniae* strains was the *aac(6')-Ib-cr* (55.6%), as reported by several studies (34).

In the study by Kim et al., performed in South Korea, 55.3% of the isolates (n = 85) were carrying the *aac(6')-Ib-cr* gene, which is consistent with the findings of the present study (35). In other studies performed by Goudarzi in Iran (city of Tehran) and Yang in Korea, the prevalence of *aac(6')-Ib-cr* gene is reported as 68.8% and 77.5%, respectively, which is higher than the prevalence reported in the present study (13, 31). Moghadam et al. reported a prevalence of 31.8% for *aac(6')-Ib-cr* gene (20). It worth noting that PMQR is mediated by the *qnr* genes, which can promote the rapid development of antibacterial resistance in the *Enterobacteriaceae* species due to being located on various integrons (9). In the current study, *qnrB* was the dominant gene (34.9%) of *qnr* genes. According to the studies performed in Iran, the prevalence of *qnrB* gene ranges from 1.6% - 88.9% (10, 13, 22). While studies conducted in other countries reported the *qnrB* as the most common *qnr* gene in *K. pneumoniae* species (36-38).

In the present study, none of the isolates was carrying the *qnrA* gene, but in the study by Moghadam et al., the fre-



**Figure 1.** Frequency of genes in single and multiple *Klebsiella pneumoniae* isolates



**Figure 2.** (Gel electrophoresis of PCR products of *qnr*/*qnrB*: 1- Lader (100 bp), 2- Negative control, 3- Positive control (594 bp), 4- Positive sample (594 bp); *qnrS*: 1- Lader (100 bp), 2- Negative control, 3- Positive sample (388 bp), 4- Positive control (388 bp); *aac(6)-Ib-cr*: 1- Lader (100 bp), 2- Positive control (482 bp), 3- Positive sample (482 bp), 4- Negative control)

quency of this gene is determined as 5.6% (20). Similar to the results of the current study, Hassuna et al., in a study performed in Egypt, couldn't detect *qnrA* gene in *K. pneumoniae* isolates (39). The co-presence of the *aac(6)-Ib-cr* and the *qnrB* genes in *E. coli* and *K. pneumoniae* samples is also reported in various conducted all around the world (27, 40-

42). The isolates carrying both genes are more resistant to aminoglycosides, cephalosporins, and quinolones, compared to those only harboring the *aac(6)-Ib-cr* gene, which highlights the pivotal role of the *qnrB* in forming this type of resistance. Other resistance mechanisms, such as mutations in the *gyrA* and *gyrC* genes or existing of *QepA* inocu-

lation pump, may also be responsible for high antibiotics resistance (43). In the present study, 37 (29.3%) isolates were simultaneously harboring *qnrB* and *aac(6′)-Ib-cr* genes. In studies performed by Alheib (in Syria) and Eftekhari (in the city of Tehran, Iran), 8 (33.3%) and 21 (50%) isolates were simultaneously carrying *aac(6′)-Ib-cr* and the *qnrB* genes, indicating a higher prevalence of antibiotic resistance compared to what was observed in the present study (10, 33).

Based on the study findings, the highest frequency of the *qnr* genes was observed in quinolone-resistant isolates. The highest prevalence rate of these genes was also reported in isolates resistant to quinolone (37). In the ESBL-producing *K. pneumoniae* strains examined in the present study, the frequency of the *qnrB* and *qnrS* genes was 46.1% (24 isolates) and 11.5% (6 isolates), respectively. In ESBL-producing isolates studied by Dehghan Benadkouki et al., 30 were carrying only one of the *qnr* genes, including the *qnrB* (n = 12, 45.7%) and *qnrS* (n = 7, 15.3%), which to a great extent is in line with the findings of the present study (23). According to Shams et al., 51.7% of ESBL-producing isolates were harboring the *qnr* genes (22). The findings of studies in the United States, Malaysia, and China on the prevalence of *qnr* genes in ESBL-producing *K. pneumoniae* isolates indicated a prevalence of 11.1, 48.9, and 65.5%, respectively (32, 37, 44).

### 5.1. Conclusions

This study showed high resistance to aminoglycosides and cephalosporins, as well as a comparatively high prevalence of fluoroquinolone-resistance genes in ESBL-producing *K. pneumoniae* strains collected from burn patients in the city of Kermanshah (Iran). Also, ESBL-producing *K. pneumoniae* isolates showed higher antibiotic resistance and more *qnr* genes were detected among them. Since burn patients experience severe life-threatening infections and due to the high antibiotic resistance in bacterial isolates inducing such infections, the results of this study are useful for developing plans to address the spread of resistant strains as well as the controlling antibiotic resistance.

### Acknowledgments

The authors hereby extend their gratitude to the Vice Chancellor's Office for Research and Technology and the Clinical Research Development Unit at Imam Reza Hospital affiliated to Kermanshah University of Medical Sciences, Kermanshah, Iran (No. 96027) for their cooperation to fulfill this study.

### Footnotes

**Authors' Contribution:** Kamal Ahmadi, Mohsen Azizi, and Siavash Vaziri: developing the study design, performing the experiments, and preparing the manuscript; Mohsen Azizi, Nahid Madadi-Goli and Kamal Ahmadi: developing the study design, performing the experiments, and writing the manuscript; Mandana Afsharian, Faizullah Mansouri, Zainab Mohseni Afshar, Mohammad Hossein Zamanian, Fatemeh Nouri, and Amirhooshang Alvandi: doing the statistical analysis, collecting the data, and drafting the manuscript. All the authors read and approved the final copy of the manuscript.

**Conflict of Interests:** The authors declare no conflict of interest.

**Ethical Approval:** The research protocol is approved by the Ethics Committee of Kermanshah University of Medical Sciences, Kermanshah, Iran (approval code no.: 1395.621).

**Funding/Support:** This research was funded by Kermanshah University of Medical Sciences, Kermanshah, Iran.

### References

1. Perween N, PraKaSh SK, Siddiqui O. Multi drug resistant klebsiella isolates in burn patients: a comparative study. *J Clin Diagn Res.* 2015;9(9):DC14. doi: [10.7860/JCDR/2015/13837.6576](https://doi.org/10.7860/JCDR/2015/13837.6576). [PubMed: 26500905]. [PubMed Central: PMC4606234].
2. Lari AR, Azimi L, Rahbar M, Alaghehbandan R, Sattarzadeh-Tabrizi M. First report of Klebsiella pneumonia carbapenemase-producing Pseudomonas aeruginosa isolated from burn patients in Iran: phenotypic and genotypic methods. *GMS hygiene and infection control.* 2014;9(1). doi: [10.3205/dgkh000226](https://doi.org/10.3205/dgkh000226). [PubMed: 24653970]. [PubMed Central: PMC4606234].
3. Vaziri S, Mansouri F, Abiri R, Alvandi A, Mortazavi SH, Ahmadi K, et al. Prevalence study of extended spectrum beta-lactamase in klebsiella pneumonia isolated from patients with ventilator-associated pneumonia in Kermanshah City, Iran. *J Isfahan Med Sch.* 2017;35(444):1113-9.
4. Beige F, Salehi MB, Bahador N, Mobasherzadeh S. Plasmid mediated antibiotic resistance in isolated bacteria from burned patients. *Jundishapur J Microbiol.* 2015;8(1). e13567. doi: [10.5812/jjm.13567](https://doi.org/10.5812/jjm.13567). [PubMed: 25789121]. [PubMed Central: PMC4350045].
5. Maleki N, Tahanasab Z, Mobasherzadeh S, Rezaei A, Faghri J. Prevalence of CTX-M and TEM  $\beta$ -lactamases in Klebsiella pneumoniae isolates from patients with urinary tract infection, Al-Zahra hospital, Isfahan, Iran. *Adv Biomed Res.* 2018;7. doi: [10.4103/abr.abr\\_17\\_17](https://doi.org/10.4103/abr.abr_17_17). [PubMed: 29456981]. [PubMed Central: PMC5812061].
6. Ghotaslou R, Sadeghi MR, Akhi MT, Hasani A, Asgharzadeh M. Prevalence and antimicrobial susceptibility patterns of ESBL, ampC and carbapenemase-producing enterobacteriaceae isolated from hospitalized patients in Azerbaijan, Iran. *Iran J Pharm Res.* 2018;17(Suppl):79. [PubMed: 29796032]. [PubMed Central: PMC5958327].
7. Gallini A, Degris E, Desplas M, Bourrel R, Archambaud M, Montastruc J-L, et al. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. *J Antimicrob Chemother.* 2010;65(12):2650-7. doi: [10.1093/jac/dkq351](https://doi.org/10.1093/jac/dkq351). [PubMed: 20876240].

8. Kammili N, Rani M, Styczynski A, Iatha M, Pavuluri PR, Reddy V, et al. Plasmid-mediated antibiotic resistance among uropathogens in primigravid women—Hyderabad, India. *PLoS One*. 2020;**15**(5):e0232710. doi: [10.1371/journal.pone.0232710](https://doi.org/10.1371/journal.pone.0232710). [PubMed: [32384111](https://pubmed.ncbi.nlm.nih.gov/32384111/)]. [PubMed Central: [PMC7209122](https://pubmed.ncbi.nlm.nih.gov/PMC7209122/)].
9. Jacoby GA, Strahilevitz J, Hooper DC. Plasmid-mediated quinolone resistance. *Microbiol Spectr*. 2014;**2**(5). doi: [10.1128/microbiolspec.PLAS-0006-2013](https://doi.org/10.1128/microbiolspec.PLAS-0006-2013). [PubMed: [25584197](https://pubmed.ncbi.nlm.nih.gov/25584197/)]. [PubMed Central: [PMC4288778](https://pubmed.ncbi.nlm.nih.gov/PMC4288778/)].
10. Eftekhari F. Prevalence of qnr and aac (6')-Ib-cr Genes in clinical isolates of Klebsiella Pneumoniae from Imam Hussein Hospital in Tehran. *Iran J Med Sci*. 2015;**40**(6):515. [PubMed: [26538780](https://pubmed.ncbi.nlm.nih.gov/26538780/)]. [PubMed Central: [PMC4628142](https://pubmed.ncbi.nlm.nih.gov/PMC4628142/)].
11. Ruiz E, Sáenz Y, Zarazaga M, Rocha-Gracia R, Martínez-Martínez L, Arlet G, et al. qnr, aac (6')-Ib-cr and qepA genes in Escherichia coli and Klebsiella spp.: genetic environments and plasmid and chromosomal location. *J Antimicrob Chemother*. 2012;**67**(4):886–97. doi: [10.1093/jac/dkr548](https://doi.org/10.1093/jac/dkr548). [PubMed: [22223228](https://pubmed.ncbi.nlm.nih.gov/22223228/)].
12. Rodríguez-Martínez JM, Díaz de Alba P, Briales A, Machuca J, Lossa M, Fernández-Cuenca F, et al. Contribution of OqxAB efflux pumps to quinolone resistance in extended spectrum- $\beta$ -lactamase-producing Klebsiella pneumoniae. *J Antimicrob Chemother*. 2013;**68**(1):68–73. doi: [10.1093/jac/dks377](https://doi.org/10.1093/jac/dks377). [PubMed: [23011289](https://pubmed.ncbi.nlm.nih.gov/23011289/)].
13. Goudarzi M, Azad M, Seyedjavadi SS. Prevalence of Plasmid-Mediated Quinolone Resistance Determinants and OqxAB Efflux Pumps among Extended-Spectrum  $\beta$ -Lactamase Producing Klebsiella pneumoniae Isolated from Patients with Nosocomial Urinary Tract Infection in Tehran, Iran. *Scientifica*. 2015;**2015**:7. doi: [10.1155/2015/518167](https://doi.org/10.1155/2015/518167). [PubMed: [26301114](https://pubmed.ncbi.nlm.nih.gov/26301114/)]. [PubMed Central: [PMC4537771](https://pubmed.ncbi.nlm.nih.gov/PMC4537771/)].
14. Wayne PA. Clinical and Laboratory Standards Institute : Performance standards for antimicrobial susceptibility testing : 20th informational supplement. *CLSI document M100-S20*. 2014.
15. Mansouri S, Kalantar Neyestanaki D, Shokoohi M, Halimi S, Beigverdi R, Rezagholezadeh F, et al. Characterization of AmpC, CTX-M and MBLs types of  $\beta$ -lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli producing Extended Spectrum  $\beta$ -lactamases in Kerman, Iran. *Jundishapur J Microbiol*. 2014;**7**(2): e8756. doi: [10.5812/jjm.8756](https://doi.org/10.5812/jjm.8756).
16. Emami S, Shafiee A, Foroumadi A. Quinolones: Recent Structural and Clinical Developments. *Iran J Pharm Res*. 2010;**4**(3):123–36. doi: [10.22037/ijpr.2010.628](https://doi.org/10.22037/ijpr.2010.628).
17. Behroozzi A, Rahbar M, Jalil V. Frequency of extended spectrum beta-lactamase (ESBLs) producing Escherichia coli and Klebsiella pneumoniae isolated from urine in an Iranian 1000-bed tertiary care hospital. *Afr J Microbiol Res*. 2010;**4**(9):881–4.
18. Bagheri-Nesami M, Rafiei A, Eslami G, Ahangarkani F, Rezaei MS, Nikkha A, et al. Assessment of extended-spectrum  $\beta$ -lactamases and integrons among Enterobacteriaceae in device-associated infections: multicenter study in north of Iran. *Antimicrob Resist Infect Control*. 2016;**5**(52):1–8. doi: [10.1186/s13756-016-0143-2](https://doi.org/10.1186/s13756-016-0143-2). [PubMed: [27980729](https://pubmed.ncbi.nlm.nih.gov/27980729/)]. [PubMed Central: [PMCS134273](https://pubmed.ncbi.nlm.nih.gov/PMCS134273/)].
19. Feizabadi M, Mahamadi-Yeganeh S, Mirsalehian A, Mirafshar SM, Mahboobi M, Nili F, et al. Genetic characterization of ESBL producing strains of Klebsiella pneumoniae from Tehran hospitals. *J Infect Dev Ctries*. 2010;**4**(10):609–15. doi: [10.3855/jidc.1059](https://doi.org/10.3855/jidc.1059). [PubMed Central: [PMC21045352](https://pubmed.ncbi.nlm.nih.gov/PMC21045352/)].
20. Moghadam MT, Shariati A, Mirkalantari S, Karmostaji A. The complex genetic Region Conferring transferable antibiotics resistance in MDR and XDR Klebsiella pneumoniae clinical isolates. *New Microbes New Infect*. 2020;100693. doi: [10.1016/j.nmni.2020.100693](https://doi.org/10.1016/j.nmni.2020.100693). [PubMed: [32670591](https://pubmed.ncbi.nlm.nih.gov/32670591/)]. [PubMed Central: [PMC7339125](https://pubmed.ncbi.nlm.nih.gov/PMC7339125/)].
21. Tahanasab Z, Mobasherzadeh S, Moghadampour M, Rezaei A, Maleki N, Faghri J. High prevalence of multiple drug resistance among ESBLs-producing Klebsiella pneumoniae isolated from hospitalized patients in Isfahan, Iran. *J Med Bacteriol*. 2016;**5**(5-6):29–38.
22. Shams E, Firoozeh F, Moniri R, Zibaei M. Prevalence of Plasmid-Mediated Quinolone Resistance Genes among Extended-Spectrum  $\beta$ -Lactamase-Producing Klebsiella pneumoniae Human Isolates in Iran. *J Pathog*. 2015;**2015**:1–7. doi: [10.1155/2015/434391](https://doi.org/10.1155/2015/434391). [PubMed: [26618005](https://pubmed.ncbi.nlm.nih.gov/26618005/)]. [PubMed Central: [PMC4649097](https://pubmed.ncbi.nlm.nih.gov/PMC4649097/)].
23. Dehghan Banadkouki A, Eslami G, Zandi H, Dehghan Banadkouki A. Prevalence of qnr genes in extended-spectrum  $\beta$ -lactamase producing Klebsiella pneumoniae isolated from clinical urine specimens in university teaching hospitals, Iran. *Int J Med Lab*. 2017;**4**(1):25–33.
24. Izadi N, Nasab MN, Mood EH, Meshkat Z. The Frequency of qnr Genes in Extended-Spectrum  $\beta$ -lactamases and non-ESBLs Klebsiella pneumoniae Species Isolated from Patients in Mashhad, Iran. *Iran J Pathol*. 2017;**12**(4):377. [PubMed: [29563934](https://pubmed.ncbi.nlm.nih.gov/29563934/)]. [PubMed Central: [PMC5844683](https://pubmed.ncbi.nlm.nih.gov/PMC5844683/)].
25. Pai H, Seo M, Choi TY. Association of QnrB determinants and production of extended-spectrum  $\beta$ -lactamases or plasmid-mediated AmpC  $\beta$ -lactamases in clinical isolates of Klebsiella pneumoniae. *Antimicrob Agents Chemother*. 2007;**51**(1):366–8. doi: [10.1128/AAC.00841-06](https://doi.org/10.1128/AAC.00841-06). [PubMed: [17074790](https://pubmed.ncbi.nlm.nih.gov/17074790/)]. [PubMed Central: [PMC1797679](https://pubmed.ncbi.nlm.nih.gov/PMC1797679/)].
26. Bouchakour M, Zerouali K, Claude JDPG, Amarouch H, El Mdaghri N, Courvalin P, et al. Plasmid-mediated quinolone resistance in expanded spectrum beta lactamase producing enterobacteriaceae in Morocco. *J Infect Dev Countries*. 2010;**4**(12):779–803. doi: [10.3855/jidc.796](https://doi.org/10.3855/jidc.796). [PubMed: [21252459](https://pubmed.ncbi.nlm.nih.gov/21252459/)].
27. Karah N, Poirel L, Bengtsson S, Sundqvist M, Kahlmeter G, Nordmann P, et al. Plasmid-mediated quinolone resistance determinants qnr and aac (6')-Ib-cr in Escherichia coli and Klebsiella spp. from Norway and Sweden. *Diagn Microbiol Infect Dis*. 2010;**66**(4):425–31. doi: [10.1016/j.diagmicrobio.2009.12.004](https://doi.org/10.1016/j.diagmicrobio.2009.12.004). [PubMed: [20226333](https://pubmed.ncbi.nlm.nih.gov/20226333/)].
28. Briales A, Rodríguez-Martínez JM, Velasco C, de Alba PD, Rodríguez-Bano J, Martínez-Martínez L, et al. Prevalence of plasmid-mediated quinolone resistance determinants qnr and aac (6')-Ib-cr in Escherichia coli and Klebsiella pneumoniae producing extended-spectrum  $\beta$ -lactamases in Spain. *Int J Antimicrob Agents*. 2012;**39**(5):431–4. doi: [10.1016/j.ijantimicag.2011.12.009](https://doi.org/10.1016/j.ijantimicag.2011.12.009). [PubMed: [22365240](https://pubmed.ncbi.nlm.nih.gov/22365240/)].
29. Peymani A, Farivar TN, Nikooei L, Najafipour R, Javadi A, Pahlevan AA. Emergence of plasmid-mediated quinolone-resistant determinants in Klebsiella pneumoniae isolates from Tehran and Qazvin provinces, Iran. *J Prev Med Hyg*. 2015;**56**(2): E61. [PubMed: [26789990](https://pubmed.ncbi.nlm.nih.gov/26789990/)]. [PubMed Central: [PMC4718354](https://pubmed.ncbi.nlm.nih.gov/PMC4718354/)].
30. Zamani A, Mashouf RY, Namvar AME, Alikhani MY. Detection of magA Gene in Klebsiella spp. Isolated from clinical samples detection of magA. *Iran J Basic Med Sci*. 2013;**16**(2):173. [PubMed: [24298386](https://pubmed.ncbi.nlm.nih.gov/24298386/)]. [PubMed Central: [PMC3843861](https://pubmed.ncbi.nlm.nih.gov/PMC3843861/)].
31. Yang HY, Nam YS, Lee HJ. Prevalence of plasmid-mediated quinolone resistance genes among ciprofloxacin-nonsusceptible Escherichia coli and Klebsiella pneumoniae isolated from blood cultures in Korea. *Can J Infect Dis Med Microbiol*. 2014;**25**(3):163–9. doi: [10.1155/2014/329541](https://doi.org/10.1155/2014/329541). [PubMed: [25285114](https://pubmed.ncbi.nlm.nih.gov/25285114/)]. [PubMed Central: [PMC4173980](https://pubmed.ncbi.nlm.nih.gov/PMC4173980/)].
32. Wang M, Sahm DF, Jacoby GA, Hooper DC. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in Klebsiella pneumoniae clinical isolates in the United States. *Antimicrob Agents Chemother*. 2004;**48**(4):1295–9. doi: [10.1128/AAC.48.4.1295-1299.2004](https://doi.org/10.1128/AAC.48.4.1295-1299.2004). [PubMed: [15047532](https://pubmed.ncbi.nlm.nih.gov/15047532/)]. [PubMed Central: [PMC375335](https://pubmed.ncbi.nlm.nih.gov/PMC375335/)].
33. Alheib O, Al Kayali R, Abajy MY. Prevalence of plasmid-mediated quinolone resistance (PMQR) determinants among extended spectrum beta-lactamases (ESBL)-producing isolates of Escherichia coli and Klebsiella pneumoniae in Aleppo, Syria. *Arch Clin Infect Dis*. 2015;**10**(3). doi: [10.5812/archcid.20631](https://doi.org/10.5812/archcid.20631).
34. Robicsek A, Strahilevitz J, Jacoby GA, Macielag M, Abbanat D, Hye Park C, et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. *Nat Med*. 2005;**12**(1):83–8. doi: [10.1038/nm1347](https://doi.org/10.1038/nm1347). [PubMed: [16369542](https://pubmed.ncbi.nlm.nih.gov/16369542/)].
35. Kim YT, Jang JH, Kim HC, Kim H, Lee KR, Park KS, et al. Identification of strain harboring both aac(6')-Ib and aac(6')-Ib-cr variant simultaneously in Escherichia coli and Klebsiella pneumoniae. *BMB*

- Rep. 2011;**44**(4):262-6. doi: [10.5483/BMBRep.2011.44.4.262](https://doi.org/10.5483/BMBRep.2011.44.4.262). [PubMed: [21524352](https://pubmed.ncbi.nlm.nih.gov/21524352/)].
36. Wang A, Yang Y, Lu Q, Wang Y, Chen Y, Deng L, et al. Presence of qnr gene in Escherichia coli and Klebsiella pneumoniae resistant to ciprofloxacin isolated from pediatric patients in China. *BMC Infect Dis.* 2008;**8**(1):68. doi: [10.1186/1471-2334-8-68](https://doi.org/10.1186/1471-2334-8-68). [PubMed: [18498643](https://pubmed.ncbi.nlm.nih.gov/18498643/)]. [PubMed Central: [PMC2409344](https://pubmed.ncbi.nlm.nih.gov/PMC2409344/)].
  37. Saiful Anuar AS, Mohd Yusof MY, Tay ST. Prevalence of plasmid-mediated qnr determinants and gyrase alteration in Klebsiella pneumoniae isolated from a university teaching hospital in Malaysia. *Eur Rev Med Pharmacol Sci.* 2013;**17**(13):1744-7. [PubMed: [23852897](https://pubmed.ncbi.nlm.nih.gov/23852897/)]. [PubMed Central: [PMC23852897](https://pubmed.ncbi.nlm.nih.gov/PMC23852897/)].
  38. Al-Marzooq F, Mohd Yusof MY, Tay ST. Molecular Analysis of Ciprofloxacin Resistance Mechanisms in Malaysian ESBL-Producing Klebsiella pneumoniae Isolates and Development of Mismatch Amplification Mutation Assays (MAMA) for Rapid Detection of gyrA and parC Mutations. *BioMed Res Int.* 2014;**2014**:10. doi: [10.1155/2014/601630](https://doi.org/10.1155/2014/601630). [PubMed: [24860827](https://pubmed.ncbi.nlm.nih.gov/24860827/)]. [PubMed Central: [PMC4000930](https://pubmed.ncbi.nlm.nih.gov/PMC4000930/)].
  39. Hassuna NA, AbdelAziz RA, Zakaria A, Abdelhakeem M. Extensively-Drug Resistant Klebsiella pneumoniae Recovered From Neonatal Sepsis Cases From a Major NICU in Egypt. *Front Microbiol.* 2020;**11**(1375). doi: [10.3389/fmicb.2020.01375](https://doi.org/10.3389/fmicb.2020.01375). [PubMed: [32636828](https://pubmed.ncbi.nlm.nih.gov/32636828/)]. [PubMed Central: [PMC7317144](https://pubmed.ncbi.nlm.nih.gov/PMC7317144/)].
  40. Martínez-Martínez L, Eliecer Cano M, Manuel Rodríguez-Martínez J, Calvo J, Pascual Á. Plasmid-mediated quinolone resistance. *Expert Rev Anti-infect Ther.* 2008;**6**(5):685-711. doi: [10.1586/14787210.6.5.685](https://doi.org/10.1586/14787210.6.5.685). [PubMed: [18847406](https://pubmed.ncbi.nlm.nih.gov/18847406/)].
  41. Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem? *Clin Microbiol Infect.* 2008;**14**(4):295-7. doi: [10.1111/j.1469-0691.2007.01930.x](https://doi.org/10.1111/j.1469-0691.2007.01930.x). [PubMed: [18190576](https://pubmed.ncbi.nlm.nih.gov/18190576/)].
  42. Poirel L, Nordmann P. Emergence of plasmid-mediated resistance to quinolones in Enterobacteriaceae. *J Antimicrob Chemother.* 2005;**56**(3):463-9. doi: [10.1093/jac/dki245](https://doi.org/10.1093/jac/dki245). [PubMed: [16020539](https://pubmed.ncbi.nlm.nih.gov/16020539/)].
  43. Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. *Ann New York Acad Sci.* 2015;**1354**(1):12-31. doi: [10.1111/nyas.12830](https://doi.org/10.1111/nyas.12830). [PubMed: [26190223](https://pubmed.ncbi.nlm.nih.gov/26190223/)]. [PubMed Central: [PMC4626314](https://pubmed.ncbi.nlm.nih.gov/PMC4626314/)].
  44. Yang H, Chen H, Yang Q, Chen M, Wang H. High Prevalence of Plasmid-Mediated Quinolone Resistance Genes qnr and aac (6')-Ib-cr in Clinical Isolates of Enterobacteriaceae from Nine Teaching Hospitals in China. *Antimicrob Agents Chemother.* 2009;**53**(2):847. doi: [10.1128/AAC.00830-08](https://doi.org/10.1128/AAC.00830-08). [PubMed Central: [PMC2592877](https://pubmed.ncbi.nlm.nih.gov/PMC2592877/)].